1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64B6C06C2215A82E200258D110030CC06
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/4B6C06C2215A82E200258D110030CC06?OpenDocument
18
19OpenDocument
2018.97.9.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Affairs Excellence

Document Excerpt: The Medical Affairs Impact Equation: Demonstrating Strategic Impact Through Outcomes and Data

DB Image

ID: MD-994


Features:

13 Info Graphics

15 Data Graphics

290+ Metrics

12 Narratives


Pages/Slides: 4


Published: 2025


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5894 “The Medical Affairs Impact Equation: Demonstrating Strategic Impact Through Outcomes and Data”.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Biopharmaceutical; Manufacturing; Consumer Products; Diagnostic; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Alcon; Alnylam Pharmaceuticals; Amgen; Astellas Pharma; Azurity Pharmaceuticals; Bayer; Boehringer Ingelheim; CSL Vifor; EMD Serono; Eton Pharmaceuticals; Eurofarma; Gilead Sciences; Grifols; Jazz Pharmaceuticals; Johnson & Johnson; Merck & Co.; Novartis; Organon; Orphalan; Otsuka; Pacira BioSciences; QIAGEN; Sanofi; Santen Pharmaceutical; Scholar Rock; Stallergenes Greer; Supernus; Syndax Pharmaceuticals; Takeda

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.